These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16393726)

  • 21. Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness.
    Langley SJ; Holden J; Derham A; Hedgeland P; Sharma RK; Woodcock A
    Chest; 2002 Sep; 122(3):806-11. PubMed ID: 12226017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients.
    Busse WW; Shah SR; Somerville L; Parasuraman B; Martin P; Goldman M
    J Allergy Clin Immunol; 2008 Jun; 121(6):1407-14, 1414.e1-6. PubMed ID: 18455221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma.
    Aubier M; Wettenger R; Gans SJ
    Respir Med; 2001 Mar; 95(3):212-20. PubMed ID: 11266239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.
    Kupryś-Lipińska I; Tworek D; Vanderbist F; Bocheńska-Marciniak M; Kuna P
    Pneumonol Alergol Pol; 2013; 81(6):527-36. PubMed ID: 24142782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma.
    Condemi JJ; Chervinsky P; Goldstein MF; Ford LB; Berger WE; Ayars GH; Rogenes PR; Edwards L; Pepsin PJ
    J Allergy Clin Immunol; 1997 Oct; 100(4):467-74. PubMed ID: 9338539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial.
    Pertseva T; Dissanayake S; Kaiser K
    Curr Med Res Opin; 2013 Oct; 29(10):1357-69. PubMed ID: 23865726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate.
    Wardlaw A; Larivee P; Eller J; Cockcroft DW; Ghaly L; Harris AG
    Ann Allergy Asthma Immunol; 2004 Jul; 93(1):49-55. PubMed ID: 15281471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.
    Corren J; Mansfield LE; Pertseva T; Blahzko V; Kaiser K
    Respir Med; 2013 Feb; 107(2):180-95. PubMed ID: 23273405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
    J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluticasone propionate compared with theophylline for mild-to-moderate asthma.
    Galant SP; Lawrence M; Meltzer EO; Tomasko M; Baker KA; Kellerman DJ
    Ann Allergy Asthma Immunol; 1996 Aug; 77(2):112-8. PubMed ID: 8760776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic exposure and urinary cortisol effects of fluticasone propionate formulated with hydrofluoroalkane in 4- to 11-year-olds with asthma.
    Kim KT; Milgrom H; Yoon YK; Levy AL; Matz P; Welch MJ; Cahn A; Collins DA; Kathman S; Mehta R; Su SF; Kunka RL
    J Clin Pharmacol; 2008 Jan; 48(1):108-16. PubMed ID: 18094223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
    Pearlman DS; Stricker W; Weinstein S; Gross G; Chervinsky P; Woodring A; Prillaman B; Shah T
    Ann Allergy Asthma Immunol; 1999 Mar; 82(3):257-65. PubMed ID: 10094216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients.
    Derom E; Van De Velde V; Marissens S; Engelstätter R; Vincken W; Pauwels R
    Pulm Pharmacol Ther; 2005; 18(5):328-36. PubMed ID: 15939311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma.
    Nathan RA; Li JT; Finn A; Jones R; Payne JE; Wolford JP; Harding SM
    Chest; 2000 Aug; 118(2):296-302. PubMed ID: 10936116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Airway and systemic effects of hydrofluoroalkane fluticasone and beclomethasone in patients with asthma.
    Currie GP; Fowler SJ; Wilson AM; Sims EJ; Orr LC; Lipworth BJ
    Thorax; 2002 Oct; 57(10):865-8. PubMed ID: 12324672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists.
    Murray J; Rosenthal R; Somerville L; Blake K; House K; Baitinger L; VanderMeer A; Dorinsky P
    Ann Allergy Asthma Immunol; 2004 Oct; 93(4):351-9. PubMed ID: 15521371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma.
    Nelson HS; Busse WW; deBoisblanc BP; Berger WE; Noonan MJ; Webb DR; Wolford JP; Mahajan PS; Hamedani AG; Shah T; Harding SM
    J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):267-75. PubMed ID: 9949318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.